Clinical trial
A Phase 1 and Phase 2 Study of Lenalidomide (Revlimid) in Combination With Cyclophosphamide (Endoxan) and Prednison (REP) in Relapsed/Refractory Multiple Myeloma
NCT01352338 is registered in ClinicalTrials.gov with UMC Utrecht as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 and Phase 2 Study of Lenalidomide (Revlimid) in Combination With Cyclophosphamide (Endoxan) and Prednison (REP) in Relapsed/Refractory Multiple Myeloma
- Lead sponsor
- UMC Utrecht
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- August 31, 2011
- Completion date
- February 29, 2016
- Enrollment
- 82 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.